A new American research will soon enable an effective therapy for cocaine toxicity.
Scientists have developed and tested a modified enzyme that can break down cocaine into inactive products nearly 1,000 times faster than the human body does regularly.
This engineered enzyme, called CocE, may be an excellent candidate for clinical use.
The difficulty in designing a therapy for cocaine toxicity stems from the drug's complex mechanism of action.
Cocaine can block multiple targets in the brain and body, which accounts for this drug's cardiovascular and anesthetic effects, as well as its strong addictive properties.
Moreover, many of the metabolites of cocaine formed by the body (such as norcocaine and cocaethylene) have similar and sometimes stronger effects than cocaine itself.
Due to the myriad of action sites that would need to be blocked to eliminate the toxic physiological effects of cocaine and its by-products, the best strategy to treating toxicity from overdose is to directly eliminate the drug.
Remy L. Brim and colleagues at the University of Michigan, in collaboration with Columbia University and the University of Kentucky, have been researching the potential of cocaine esterase (CocE) to block cocaine toxicity by eliminating cocaine.